HDAC inhibitor-based therapies: can we interpret the code?
Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone dea...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
2012
|